INTRODUCTION
Being the most frequently diagnosed female cancer worldwide, breast cancer is always a mystifying puzzle, owing to its highly heterogeneous and complex nature. The molecular intricacies associated with breast cancer raise a unique curiosity among the researchers to unravel the mystery behind the wide contrast in responsiveness to treatments by the different subtypes of breast cancer. The expression status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2/neu) is highly significant in clinical scenario due to the influence of these trios in dictating the response of breast cancer cells to the currently available chemotherapeutic agents.
1,2 Hormonal receptors are ideal therapeutic targets and tumors overexpressing them usually respond well to hormonal therapy. 3 On the contrary, the HER-2 overexpression is considered as a clinical dilemma, which often portends tumour aggressiveness and chemotherapeutic resistance in tumor cells. In 20-25% of invasive breast cancers, HER-2 gene is either overexpressed or amplified. 4 As an epidermal growth factor receptor (EGFR), HER-2 is not known to bind with any known ligands but can heterodimerize with other related EGFR family members. By doing so, it could recruit various adaptor proteins, which in turn lead to the activation of multiple signal transduction cascades including RAF-MEK-ERK and PI3K/AKT/mTOR pathways. 5 All these signaling events activated on HER-2 overexpression provide a pro-survival environment in breast cancer cells leading to chemotherapeutic resistance. Docetaxel, an FDA-approved taxane frequently used for frontline therapeutic treatment of breast cancer, exerts its cytotoxicity by altering the dynamics of tubulin formation in cancer cells. 6 Although docetaxel is efficient in blocking its target, the general inefficiency of this drug to overcome the survival signals, which get activated in response to its treatment, often leads to chemotherapeutic resistance and even to tumor relapse. Multiple survival mechanisms accounting to the docetaxel resistance include enhanced activity of drug efflux pumps and increased activation of general survival signals. 7 There are ample evidence regarding the activation of survival signals including the prominent kinase networks such as mitogen-activated protein kinase (MAPK) and PI3K/Akt or the transcription factor such as nuclear factor-κB (NF-κB) and AP-1 in response to docetaxel treatment, which in turn could create a cellular pro-survival environment leading to apoptosis resistance. 1 Chemosensitization is an attractive strategy to surmount such drawbacks involved in docetaxel treatment. A compound that can efficiently downregulate the survival signals activated by docetaxel can act as a chemosensitizer and can enhance its efficacy. Several pharmacologically safe phytochemicals have been reported to act as potent chemosensitizers in combination with conventional chemotherapeutic drugs. 8, 9 Resveratrol, a natural chemopreventive, is one among them and possesses all attractive traits such as multi-targeting efficacy, pharmacological safety, immediate availability and cost effectiveness, which are required for a classic chemosensitizer. [10] [11] [12] The relationship between HER-2 signaling and taxane resistance are mediated through activation of PI3K/Akt and upregulation of survivin, a factor known to help the tumor cells to avoid taxane toxicity by inducing an early mitotic exit. [13] [14] [15] [16] Similarly, HER-2 is shown to influence the multi-drug efflux pump activation, a crucial factor known to provide resistance against drugs including taxanes, through MAPK-STAT-3 signaling axis. 15, 17, 18 Reviewers who meta-analyzed the reports on docetaxel resistance noted a battery of such signaling networks with HER-2 as its focal point, which helps them to relegate this receptor as a governing factor of taxane resistance. 15 However, the practical attempt to enhance the efficacy of chemotherapeutic agents by blocking HER-2 receptor molecule has so far been not successful as expected.
Here we show that resveratrol as a combination with docetaxel blocks HER-2 expression and its activation in addition to blocking downstream signaling pathways such as Akt. Resveratrol and docetaxel combination results in the synergistic induction of cell death in HER-2-overexpressing SK-BR-3 cells, whereas introduction of wild-type HER-2 in MDA-MD-231 cells increased the resistance to docetaxel. Dominant-negative HER-2 sensitizes SK-BR-3 cells to docetaxel. Our study, for the first time, identified a novel therapeutic combination that targets HER-2-induced breast cancer resistance to induce apoptosis synergistically and might help to overcome therapeutic resistance during breast cancer therapy.
RESULTS
Docetaxel and resveratrol exerts synergistic cytotoxic effect in breast cancer cells, while normal immortalized breast epithelial cells are unaffected Cell viability assay was performed to evaluate the cytotoxic effect of docetaxel and resveratrol toward breast cancer cells (SK-BR-3, MCF7, MDA-MB-231 and T47D) with varying receptor status. Both the compounds induced dose-dependent cytotoxicity toward the cell lines tested (Figures 1a and b) . Various combinations of docetaxel and resveratrol were evaluated for their cytotoxic effect, where a combination of 15 μM resveratrol and 1 nM docetaxel was found to induce synergic cytotoxicity (Figure 1c) , which was maximum in SK-BR-3 and minimum in MDA-MB-231, while being moderate in MCF-7 and T47D. The synergistic response exhibited by different breast cancer cell lines to the combination has been depicted in Figure 1c . The contrast in the synergistic response of SK-BR-3 and MDA-MB-231 was evident in the combinative index (CI) values of the combination. CI of SK-BR-3 ranges from 0.32 to 0.51, which is o1, indicating clear synergism, whereas that of MDA-MB-231 ranges from 0.94 to 1.21, which is ⩽ 1, indicating additive effect. Hence, SK-BR-3 was selected for further evaluation of the combination and the synergism was confirmed by [ 3 H] thymidine incorporation assay (Figure 1d ). According to the results, docetaxel and resveratrol in combination exerts cytotoxic effect, which is more or similar to the cytotoxicity induced by five times higher concentration of docetaxel alone, whereas resveratrol alone did not induce a significant cell death (Figures 1c and d) . The biological safety of the combination was ensured in normal immortalized breast epithelial cell line, MCF10A by [H] 3 thymidine incorporation assay (Figure 1e) . Furthermore, the combination of resveratrol with docetaxel drastically blocked the clonogenic potential of SK-BR-3 cells (Figure 1f ).
The synergism of docetaxel and resveratrol in SK-BR-3 cells is evidenced by enhancement in apoptosis Various apoptotic assays were performed, to confirm the results obtained from the preliminary cytotoxic evaluation of the combination. The results obtained from Annexin V/propidium iodide staining was in concordance with that of MTT assay. SKBR-3 cells treated with the combination exhibited a significant enhancement in externalization of phoshatidyl serine, an early event of apoptosis, compared with that treated with either of these compounds alone (Figure 2a) . The combination induced a momentous cleavage of pro-caspase-8 to its active fragment (p18 ) compared with the cells treated with either of the two compounds alone (Figure 2b ). The combination also induced the cleavage of procaspase-9, procaspase-3 and procaspase-7 to their active fragments (Figures 2c-e) and a significant enhancement in the cleavage of PARP, the downstream target of caspase cascade (Figure 2f ). In addition, treatment with the combination induced a tremendous accumulation of cells in sub-G0 phase (28.1%), confirming the induction of apoptosis by the combination as assessed by PI-FACS analysis. However, resveratrol treatment did not induce a significant enhancement in docetaxel-induced cell cycle arrest ( Figure 2g ). Moreover, an enhancement in the internucleosomal cleavage of DNA, the biochemical hallmark of apoptosis, was also observed in cells treated with combination ( Figure 2h ).
HER-2 has a dominant role in offering resistance to docetaxel As docetaxel achieves its therapeutic efficacy by inhibiting the depolymerization of tubulin and thereby inducing cell cycle arrest, it was surprising to notice that the combination induced a maximum synergistic effect in SK-BR-3 cells among the different breast cancer cell lines studied, while resveratrol did not induce a significant enhancement in docetaxel-induced G2/M arrest in these cells ( Figure 2g ). This observation logically led us to analyze the difference between the selected cell lines and thus ended up in noting a striking difference in HER-2 expression among them. Although SK-BR-3 is a HER-2-overexpressing cell line, all others express this receptor only at a moderate level. 19 Hence, we assumed a significant role for HER-2 signaling in the synergism. Interestingly, docetaxel treatment induced further increase in the expression level of HER-2 in SK-BR-3 cells (Figure 3a) , which prompted us to evaluate the efficacy of resveratrol in regulating it. Supporting our hypothesis, resveratrol treatment significantly abrogated the basal and docetaxel-induced expression of HER-2 in SK-BR-3 cells (Figure 3b) . Concomitantly, the phosphorylation of HER-2, which is an indication of its activity, was also increased on docetaxel treatment and was completely abolished by resveratrol (Figure 3c ). To evaluate the role of HER-2 in regulating the synergism, HER-2 signaling was inhibited in SK-BR-3 cells by transfecting DN-HER-2 [K753M] and overexpressed in MDA-MB-231, the triple-negative cell line, by transfecting WT-HER-2, and the synergism was evaluated in these cells and compared with that of vector-transfected cells. Interestingly, the synergism was completely abolished in DN-HER-2-transfected cells, whereas it was persistent in vector-transfected cells (Figure 3d ), as the inactivation of HER-2 itself sensitizes the cells to docetaxel and hence there is no significant role for resveratrol as a chemosensitizer. On the contrary, the HER-2-overexpressed MDA-MB-231 cells exhibited resistance to docetaxel compared with its vector-transfected counterparts, whereas its response to resveratrol or to the combination of docetaxel and resveratrol remains unchanged. This, in effect, leads to a significant enhancement of the synergism in HER-2-overexpressed MDA-MB-231 cells, as the introduction of HER-2 contributed to docetaxel resistance, thereby furnishing a chemosensitizing role to resveratrol (Figure 3e ). Taken together, these results demonstrate that HER-2 confers resistance to docetaxel and resveratrol overcomes it.
HER-2 downstream effector Akt is the pivotal molecule that offers resistance to docetaxel and resveratrol downregulates all major survival pathways induced by docetaxel, except NF-κB We next examined the role of MAPK, Akt and NF-κB -the survival pathways known to act downstream of HER-2 [20] [21] [22] phosphorylation (Figure 4d ), which was significantly inhibited on pretreatment of resveratrol (Figure 4e ). This pattern of signaling modulation of MAPK in response to docetaxel and resveratrol was also reflected in the nuclear translocation and DNA binding of AP-1, a signaling event downstream of MAPK, as evident in the electrophoretic mobility shift assay (EMSA; Figure 4f ). Super-shift assay was conducted to confirm the specificity of AP-1 band (Figure 4g ). Docetaxel also induced a transient nuclear translocation of NF-κB (Figure 4h) . Surprisingly, resveratrol failed to downregulate this activation of NF-κB (Figure 4i ) at the concentration studied (15 μM), although it is a known inhibitor of NF-κB. 23 As the pattern of signaling modulation exerted by the docetaxel and resveratrol on HER-2 was mirrored in the activation pattern of MAPK and Akt, we hypothesized that any of these HER-2 downstream signaling molecules might act as a major mediator of HER-2-induced resistance to docetaxel.Although inhibition of Akt by LY294002 sensitized SK-BR-3 cells to singleagent docetaxel, inhibition of MAPK pathway by their corresponding inhibitors could not do so, indicating that Akt, but not the MAPK signaling, confers resistance to docetaxel (Figure 4j ). HER-2 is coupled to Akt axis in regulating the synergism We have gathered further proof for the existence of HER-2-Akt signaling axis in regulating the synergism. We verified that Akt activity is coupled to HER-2 signaling in SK-BR-3 cells by demonstrating the inhibition of basal Akt signaling in DN-HER-2-transfected cells (Figure 5a ). We found that docetaxel could not induce Akt activation in these cells, attesting that arbitration of HER-2 is necessary for docetaxel to induce Akt (Figure 5b ). It is interesting to note that Akt inhibition neither blocks HER-2 from being induced in response to docetaxel nor prevent HER-2 from being inhibited in response to the combination of docetaxel and resveratrol, verifying that Akt is downstream of HER-2 ( Figure 5c ). The independent regulatory role of resveratrol on kinase activity of all three classes of Akt was confirmed by z-lite biochemical assay platform, where isolated Akts (Akt1, Akt2 and Akt3) were screened against resveratrol. Interestingly, the results shows that resveratrol induces maximum inhibition to Akt-2, which is the focus molecule of current study (Figure 5d ).
The response of Akt to docetaxel and resveratrol was also reflected in the expression pattern of the downstream signaling molecules. Resveratrol downregulated docetaxel-induced overexpression of survivin, a pro-survival protein, extensively regulated by Akt 24 (Figure 5e ). Although XIAP is generally considered as an NF-κB-dependent gene, it has been shown to be a major target of Akt at post-mitochondrial level. 25 We found that docetaxelinduced activation of XIAP is downregulated by resveratrol (Figure 5f ). Another survival signal, which gets activated in response to the activation of PI3K/Akt pathway is Bcl-2 (Asnaghi, 2004) . We observed a time-dependant upregulation of Bcl-2 by docetaxel, which was clearly downregulated by pretreatment with resveratrol ( Figure 5g ). Taken together, these results demonstrate the efficacy of resveratrol in overcoming docetaxel-induced HER-2 activation and its downstream survival signal Akt, which is pivotal in resveratrol-induced chemosensitization of breast cancer cells to docetaxel. Figure 6 illustrates our findings in a nutshell.
DISCUSSION
Meta-analysis of the articles describing the anti-tumor efficacy of docetaxel reveals that activation of the general pro-survival signals such as MAPK, NF-κB and Akt in response to docetaxel are the frequently reported reasons for docetaxel chemoresistance. According to the previous studies reporting the mechanism of resveratrol-mediated chemosensitization, the multifaceted efficacy of resveratrol in inhibiting the general pro-survival mechanisms, including the above mentioned signals, forms the very basis of its chemosensitizing property. 8, 10, 26 Our results justify the rationale involved in selecting the combination of these drugs, by demonstrating the efficacy of resveratrol in enhancing the signature events of apoptosis such as DNA fragmentation, PARP cleavage and caspase activation induced by docetaxel. However, the correlation observed between the HER-2 expression status of breast cancer cells and their response to the synergistic combination of docetaxel and resveratrol, as described in the Results section, prompted us to approach this study with a perspective based on HER-2 expression status of the breast cancer cells.
Among the growth factor receptors regulating the pro-survival signaling environment in breast cancer cells, HER-2 is deemed important, especially in patient context, because of the influence it exerts on chemoresistance against taxanes. Tumor cells with receptor status profiles similar to that of triple-negative cells (ER ) is reported to have a greater sensitivity to taxanes such as paclitaxel than HER-2-amplified cells. 15, 27 SK-BR-3, a cell line that exhibit relatively superior synergism to docetaxel-resveratrol combination, has a higher HER-2 expression status but a lower ER and PR levels, whereas MDA-MB-231, a cell line that exhibits reduced sensitivity to the combination of docetaxel and resveratrol, has a reduced expression of all the three receptors. 19 It is against this , which differ only in their HER-2 status, forms ideal tools for studying its role without the signaling noise from ER and PR receptors. 19 As major research attempts are devoted so far for improving the chemotherapeutic efficacy by inhibiting HER-2 expression, 28, 29 the evidence regarding the efficacy of resveratrol in antagonizing docetaxel-induced HER-2 upregulation gains significance.
The activity of HER-2 is reported to be mediated through survival signaling pathways such as MAPK and PI3K/Akt. 2, 5 A relatively recent report demonstrates that HER-2 could also positively influence the pro-survival environment of tumor cells through NF-κB mediation. 20 These signaling molecules, once activated through HER-2, could exert regulations on apoptosis centers and thus mount resistance against stresses by creating a pro-survival environment. 5 Among them, Akt is the most discussed molecule in connection with HER-2 resistance. 13 There are reports citing the strong influence of HER-2-Akt signaling axis on tumor resistance against classic chemotherapeutic drugs. 13 However, the clinical attempts to block this vicious axis using specific HER-2 inhibitors such as Herceptin have met with limited success in clinical trials. One of the reasons pointed out for its failure are the existence of signals capable of activating Akt pathway, independent of HER-2, thus overriding the effect of Herceptin-mediated HER-2 inhibition. 16 Resveratrol may perhaps have advantage over such quintessential HER-2 inhibitors, as it could block HER-2 and the enzymatic activity of Akt independent of HER-2 as evident from our results. This might help resveratrol to negate all pro-survival signals induced by docetaxel and mediated through Akt. This efficacy of resveratrol in regulating enzymatic activity of Akt independent of HER-2 might be the reason for its synergistic effect with docetaxel in all breast cancer cells screened, irrespective of their HER-2 status.
The extent at which activated Akt exerts its influence over crucial apoptosis regulating molecules should be considered at this context. For instance, survivin and XIAP, members of inhibitors of apoptosis family, are downstream of Akt pathway and are capable of resisting apoptosis induced by classic chemotherapeutic agents including taxanes. 25 The upregulation of survivin mediated through HER-2-Akt axis has been shown as a reason for the early mitotic exit and thus as a factor influencing the taxane resistance. 15 Similar is the case of Bcl-2, an anti-apoptotic protein whose activation through Akt helps the cells to maintain . Western blotting analysis was done against anti-XIAP. The cells were pretreated with resveratrol for 24 h followed by docetaxel alone or in combination with resveratrol for another 16 h and western blot analysis was performed using antibody against anti-XIAP. (g) Kinetics of docetaxel-induced activation of Bcl-2 and inhibition of the same by synergistic combination of resveratrol and docetaxel. Cells were treated with of docetaxel for different time intervals (0-48 h). Western blot analysis was performed against anti-Bcl-2. Cells were pretreated with resveratrol followed by combination of resveratrol and docetaxel for 4 h. Whole-cell lysate was immunoblotted using anti-Bcl-2. β-Actin was used as loading control in all the experiments. mitochondria in an anti-apoptotic signaling mode during a chemotherapeutic insult. 30 As resveratrol is capable of blocking pro-survival signals mediated through these molecules induced by docetaxel, most probably by blocking HER-2-Akt signaling axis, it is conceivable that blockage of these signals by resveratrol enhances the chemotherapeutic efficacy of docetaxel.
In short, this study, for the first time, illustrates a mechanismbased evidence for the potential utility of resveratrol in overcoming HER-2-mediated chemoresistance of docetaxel in breast cancer cells. However, before proceeding to clinical trials, the proposed mechanism needs further validation using in vivo models.
MATERIALS AND METHODS

Cell lines
The breast cancer cell lines SK-BR-3, MCF7, MDA-MB-231 and T47D were purchased from National Centre for Cell Sciences (Pune, India) and the normal immortalized breast epithelial cell line MCF10A (ATCC, Manassas, VA, USA) was a gift from Dr S Sreeja (Rajiv Gandhi Centre for Biotechnology).
Chemicals
Dulbecco's modified Eagle's medium was obtained from Life Technologies (Grand Island, NY, USA); antibodies against caspases, phospho-ERK1/2, phospho-JNK, phospho-p38, Akt, phospho-Akt, phospho-Bad, HER2 and phospho-HER2 were obtained from Cell Signaling (Beverly, MA, USA); and those against c-Jun, survivin, XIAP, Bcl-2 and PARP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Resveratrol was purchased from Calbiochem (San Diego, CA, USA). All other chemicals including docetaxel were purchased from Sigma Chemicals (St. Louis, MO, USA).
Mode of treatment
In all combination treatments, resveratrol (15 μM) was added 24 h before docetaxel (1 nM) treatment unless otherwise mentioned. The DMSO concentration in all experiments, including controls, was r 0.2%.
MTT assay
Proliferative/cytotoxic effect of docetaxel and/or resveratrol was determined by MTT assay as described earlier. 31 
Statistical analysis
The error bars represent ± S.D. of the experiments. For the flow cytometry, data analysis was carried out using the BD FACS Diva software, version 5.0.2 (Becton Dickinson and Company, Franklin Lakes, NJ, USA). The comparison of mean data among multiple groups was analyzed by ANOVA; ***P-values ≤ 0.001, **P-values ≤ 0.01 and *P-values ≤ 0.05; ns represents nonsignificance.
Determination of combinatorial effects
The CI was determined as described by Chou and Talalay. 32 Combinations having CI value o1 were taken as synergistic, those with CI value = 1 were taken as additive and those with CI values 41 were taken as antagonistic. The most effective synergistic combination was selected for further studies.
[ 3 H]thymidine incorporation assay [ 3 H]thymidine incorporation assay was performed to assess inhibition of DNA synthesis induced by various drugs as described earlier. 31 
Clonogenic assay
Clonogenic assay was performed in SK-BR-3 cells treated with required concentrations of resveratrol and docetaxel alone and in combination as descried. Briefly, 500 cells were seeded in 12-well plates and treated with docetaxel (1 nM) and resveratrol (15 μM), alone or in combination. After 72 h, the plates were replaced with fresh medium and incubated for 1 week. The clones developed were fixed in gluteraldehyde and stained using crystal violet. The clones were counted and compared with the control. Colony containing more than ten cells was counted as one clone. 33 Western blot analysis Total protein isolated from cells after indicated treatments were subjected to western blotting as described earlier. 
Cell cycle analysis
The cell cycle analysis was conducted as reported earlier. 31 Preparation of nuclear extracts and EMSA assay EMSA assay was performed to evaluate DNA-binding activity of NF-κB or AP-1 as described earlier. 31 Transfection SK-BR-3 cells were transiently transfected with empty vector and HER2 dominant-negative plasmid, whereas MDA-MB-231 cells were transfected with empty vector and HER2 wild-type plasmids (both plasmids were a kind gift from Dr Mien-Chie Hung, Department of Molecular and Cellular Oncology, MD Anderson Cancer Center, Houston, TX, USA) using Lipofectamine 2000 reagent according to the manufacturer's protocol (Invitrogen, Life Technologies, Grand Island, NY, USA). Briefly, the diluted DNA sample and the transfection reagent were mixed in 1 : 1 ratio and added to 60-70% confluent cells and incubated for 5-7 h before replacing transfection media with the normal growth media. 31 
ABBREVIATIONS
HER-2, human epidermal growth factor receptor-2; NF-κB, nuclear factor-κB; MAPK, mitogen-activated protein kinase. 
